COMP <GO>
NMTC vs JNJ // ENTERPRISE SCALE & MARKET CAP
NeuroOne Medical Technologies Corporation (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: NMTC 1
— JNJ 7
▲ ENTERPRISE SCALE & MARKET CAP LEADER: JNJ
LAST: $0.97 (+12.96%) • MKT CAP: $8.8M
market-cap
$8.8M
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
market-cap
$662.49B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NMTC VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NMTC | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.50% | 67.90% | -11.40 | JNJ | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 2.97% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -46.50% | 34.70% | -81.20 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -39.60% | 28.50% | -68.10 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 163.50% | 6.00% | +157.50 | NMTC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.59 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 40.1 | 62.1 | -22.00 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $8.8M | $662.49B | -$662.48B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NMTC REV | JNJ REV | NMTC GROSS % | JNJ GROSS % | NMTC FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $9.1M | $94.19B | 56.5% | 67.9% | -$2.9M | $19.70B |
| FY 2024 | $3.5M | $88.82B | 31.3% | 69.1% | -$11.1M | $19.84B |
| FY 2023 | $2.0M | $85.16B | — | — | -$12.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NMTC // BETA —
JNJ // BETA 1.08